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RESEARCH ARTICLE
Profile of medical care costs in patients with amyotrophic lateral
sclerosis in the Medicare programme and under commercial
insurance
LISA MENG1, AMY BIAN2, SCOTT JORDAN2, ANDREW WOLFF2,
JEREMY M. SHEFNER3 & JINSY ANDREWS2*
1Cytokinetics, Inc, Cupertino, CA, USA, 2Cytokinetics, Inc, South San Francisco, CA, USA, and 3Department of
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Abstract
Objective: To determine amyotrophic lateral sclerosis (ALS)-associated costs incurred by patients covered by Medicare and/
or commercial insurance before, during and after diagnosis and provide cost details. Methods: Costs were calculated from
the Medicare Standard Analytical File 5% sample claims data from Parts A and B from 2009, 2010 and 2011 for ALS
Medicare patients aged 70 years (monthly costs) and 65 years (costs associated with disability milestones). Commercial
insurance patients aged 18–63 years were selected based on the data provided in the Coordination of Benefits field from
Truven MarketScan in 2008–2010. Results: Monthly costs increased nine months before diagnosis, peaked during the
index month (Medicare: $10,398; commercial: $9354) and decreased but remained high post-index. Costs generally
shifted from outpatient to inpatient and private nursing after diagnosis; prescriptions and durable medical equipment costs
were much higher for commercial patients post-diagnosis. Patients appeared to progress to disability milestones more
rapidly as their disease progressed in severity (14.4 months to non-invasive ventilation [NIV] vs. 16.6 months to hospice),
and their costs increased accordingly (NIV: $58,973 vs. hospice: $76,179). Conclusions: For newly diagnosed ALS patients
in the U.S., medical costs are substantial and increase rapidly and substantially with each disability milestone.
Keywords: Medical care costs, amyotrophic lateral sclerosis, Medicare, insurance
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurode-
generative, progressive motor neuron disease lead-
ing to paralysis and death from respiratory failure
typically within three to five years of diagnosis (1).
No cure exists and the only drug shown to increase
survival does so modestly (2). ALS management is
primarily supportive (3), increasing with time and
requiring greater assistance and intervention leading
to escalating cost burden (4–8). Despite this burden,
little has been published on costs associated with
disease progression in patients with ALS (9).
Most previous studies examining ALS-
associated costs were conducted in restricted patient
populations and outside of the United States (U.S.).
For example, studies examining direct and indirect
costs associated with ALS (as defined by each study)
have been conducted in Germany (n¼ 46) (10),
Ireland (n¼ 119) (11), Canada (n¼ 49) (12) and
Greece (n¼ 33) (13). The Canadian study also
calculated personal economic impact (e.g. substan-
tial out-of-pocket expenses) on ALS patients (12).
Moreover, cost and ALS disease severity rela-
tionships have been studied in Spain (5), the
Netherlands (8), the United Kingdom (6),
Denmark (14) and Korea (7), and most found that
costs increased with disease severity across the
course of the disease.
Costs in the U.S. may differ because unlike
countries such as Canada, Japan and most
European countries that have universal healthcare
(12,15–19), the U.S. has many commercial providers
that have different contracts with different health-
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care and medical supplies providers. Moreover, the
U.S. also uses joint commercial and government-
funded Medicare insurance. Medicare is generally
available for U.S. citizens once they turn 65 years of
age but is available for individuals upon diagnosis of
ALS regardless of age (20) and transitioning to
Medicare frequently offers ALS patients access to
additional services.
The one U.S. national retrospective cost-of-
illness study (n¼ 1528), estimated total annual
costs of ALS using commercial and Medicare
claims as $256–433 million (in 2010 dollars) (4).
Although the total national cost of ALS calculated
(4) is substantially lower than that of Parkinson’s
disease – estimated to exceed $14.4 billion (in 2010
dollars) (21) – average annual cost per ALS patient
is substantially higher ($63,693 vs. $22,800 in
2010 dollars). This underscores the need to better
understand cost accrual during ALS progression,
especially in the current health economic market
where the Centers for Medicare and Medicaid
Services, the Joint Commission and private payers
are focussed on cost reduction in the U.S. (9).
The primary objective of this research was to
characterise medical costs, as measured by claims
data, incurred by ALS patients in the U.S. covered
by Medicare and/or by commercial insurance to
determine ALS-associated costs before, during and
after diagnosis and provide cost details, including by
service category. Because patients with commercial
insurance may become eligible for Medicare during
the course of their disease, this study also sought to
examine ALS medical care costs before and after
diagnosis under each programme and during the
transition between insurances.
Methods
Data sources
Medical costs per patient were calculated using data
from the Medicare Standard Analytical File (SAF)
5% sample claims data from Part A and Part B
beneficiaries covered in 2009, 2010 and 2011 and
from Truven MarketScan, a proprietary claims
database for members of a large (40 million
commercially insured lives) national insurance plan
containing claims and enrolment information during
2008–2010. Information on claims paid and demo-
graphics (for longitudinal tracking) and on diagno-
sis, procedures and drug details using standard
coding systems (i.e. ICD-9 diagnosis code 335.20
[ALS] with no claims with diagnosis-related group
codes 58, 59, or 60 [multiple sclerosis and cerebellar
ataxia]) were obtained. Use of claims from these two
sources allowed for comparison of costs on each and
during the unique transition from commercial
insurance to Medicare that individuals make when
diagnosed with ALS in the U.S.
Case selection
ALS patients were identified as having one inpatient
claim, one emergency room (ER) visit or two or more
physician outpatient claims with ICD-9 diagnosis
code 335.20 (ALS) and no claims with diagnosis-
related group codes of 58, 59 or 60. As ALS is
diagnosed clinically, the chance of misdiagnosis
cannot be excluded. However, the requirement of
2 encounters with the ALS diagnosis code reduces
this chance, and overall diagnostic accuracy of ALS
by neurologists is high (499.9% observed in large,
late-stage ALS studies). Cases were considered new
if there were no claims coded as related to ALS from
the previous year. Analyses were limited to Medicare
patients aged 70 years to identify ALS patients
newly diagnosed while on Medicare and who had
Medicare coverage before their diagnosis. To ensure
similar numbers of pre- and post-index (i.e. date of
ALS diagnosis) cases and that each case had com-
plete insurance claim data during the cost-estimation
period, criteria used to identify pre-index and post-
index Medicare cases differed slightly. To estimate
monthly post-index ALS costs, patients whose index
date occurred after 1 January 2009 and whose death
occurred before 31 December 2011 were identified,
whereas to estimate monthly pre-index costs,
patients whose index date occurred after 1 January
2010 were identified because before 2009 exact dates
of Medicare claims were not reported and so these
data were not available to estimate pre-index monthly
costs. To better understand time and costs to
disability, the patient cohort was expanded to
patients aged 65 years.
Commercial insurance patients aged 18–63 years
whose index date occurred in 2010 and who were
enrolled continuously for at least one year before
their index date, were identified to estimate pre-
index monthly costs. To study ALS cost allocation
by payer, patients were selected based on data
provided in the Coordination of Benefits (COB)
field in the MarketScan data. Once a patient is
eligible for Medicare, the amount paid by Medicare
is recorded in the COB field; allowed costs are total
COB plus amounts paid by commercial plans and
by patients. However, not all data contributors to
MarketScan provided detailed data to allow this
tabulation. To exclude these cases and cases eligible
for Medicare before the index dates, patients for
study of cost allocation by payer were selected as
follows: 1) having COB in one month or more after
index month; 2) not having COB before or in index
month; 3) having COB that is always positive; 4)
having COB that is always below allowed costs; and
5) having an index date before 1 July 2010.
Disability milestones
Disability milestones were defined according to the
Healthcare Common Procedure Coding System
(22), a standardised coding system based on the
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American Medical Association’s Current Procedural
Terminology that describes specific items and ser-
vices provided. The items/services selected as mile-
stones of ALS severity (Table 1) focussed on clinical
outcomes recognised as being correlated with ALS
progression (i.e. loss of limb movement and need for
respiratory support) (23).
Statistical analyses
Demographic information and claims data were
summarised descriptively. Average costs from
claims submitted for reimbursement were provided
by periods relative to index dates and insurance
programme: patients whose initial ALS diagnosis
occurred while they were covered by Medicare were
defined as ‘pure’ Medicare, whereas patients whose
initial ALS diagnosis occurred while they were
covered by commercial insurance were included
with commercial data. To avoid complications from
the transition from commercial insurance to
Medicare, pure Medicare and commercial data
were analysed separately. Monthly average claims
costs per patient were tabulated from one year before
index date until death or through 2010. Costs before
and after the index date were modelled exponentially
in a piecewise fashion. Medical costs from index date
to disability milestones (defined only by claims) were
tabulated from the Medicare database.
Missing insurance claim lifetime data is the major
challenge for recently developed analytical
Table 1. Disability milestones as defined by the Healthcare Common Procedure Coding System (22).
Level HCPCS Rev code ICD-9 dx code
1 Canes E0100
E0105
2 Walkers and accessories E0150-E0159
3 Wheelchairs and accessories E0950-E1298
97542
E2201-E2397
E2601-E2625
K0001-K0899
4 Artificial nutrition 43246
43760
43761
44373
49440
49441
49446
49450
49451
49452
B4043-B4162
B9000
B9002
B9998
5 Non-invasive ventilation E0464
E0470
E0471
A7030-A7039
A7044-A7046
6 Invasive ventilation A4611-A4613
A4623-A4626
A4629
A4483
E0460-E0461
E0463
E0472
E0450
A7501-A7527
94002-94005
7 Speech-generating devices and accessories E2500-E2599
92607
92608
92609
8 Hospice 99377 0650 V66.7
99378 0651
0655
0656
0657
0659
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approaches for cost data in this study. Kaplan-Meier
estimator is used frequently to measure the fraction
of patients starting from a defined point to the
occurrence of a given event and the length of time
that patients remain free of that event, and it allows
for situations such as patients not having follow-up
data or not reaching disability or death during the
study up to 2010. Because of the nature of ALS
disease progression and the coverage of the Medicare
programme, the two key assumptions for the Kaplan-
Meier estimator–(1) patients would experience dis-
ability events eventually until they die or these events
would be truncated to the end of the follow-up period
and (2) the censoring pattern was independent of the
disability occurrence time–seemed valid. Therefore,
Kaplan-Meier estimator was used.
Kaplan–Meier Sample Average (KMSA) total
costs from the index date to a disability milestone
was constructed by obtaining the average monthly
cost and the corresponding monthly disability-
event-free probability of Kaplan-Meier estimator
up to the month when the last patient developed
that disability. The sum of the products of these two
monthly components becomes the KMSA estimator
of total cost for that milestone. The estimated cost
for later disability milestones, therefore, included
the cost for prior milestones.
Results
Demographics
In total, 655 new ALS patients in Medicare were
identified. From these, 222 patients aged 70 years
whose index date occurred after 1 January 2010
were selected to estimate monthly costs before the
index date. Also, 217 patients aged 70 years and
whose index date occurred after 1 January 2009 and
who died before 31 December 2011 were selected to
estimate monthly post-index costs and time and
costs to disability milestones. To expand the dis-
ability milestones analysis, the range for patient age
was lowered to 65 years, identifying 368 ALS
patients whose index date occurred after 1 January
2009.
In the commercial database, 891 new ALS
patients were identified. From these, 266 patients
aged 18–63 years whose index diagnosis occurred in
2010 and who were enrolled for at least one year
before their index date were selected to estimate pre-
index monthly costs. There were 78 patients who
satisfied COB criteria selected to estimate the
monthly post-index costs.
Monthly direct costs – pure Medicare patients
Monthly costs increased nine months before the
diagnosis was made (Figure 1), with the highest-cost
month being the month of diagnosis (index month)
(Table 2). Costs were lower in the month following
the index month but were still higher after diagnosis
than they were pre-diagnosis. Total costs in the
months following diagnosis were substantial and
increased with longer survival times (Figure 2).
Inpatient facility costs accounted for most costs
incurred in the index month and were over $600
higher in the final month of life versus the post-
index period. In contrast, costs associated with
durable medical equipment (DME) were highest in
the months following the index month and were
lower in the final month of life (Table 2). Private
duty nursing/home health costs also increased across
the study period.
Monthly direct costs – pure commercial patients
Similarly, the highest-cost month for patients with
commercial insurance was the index month, with
monthly costs increasing during the nine months
before the index month (Figure 3). The average
claim paid by commercial insurance in the index
month was $9354, $1044 less than the average
claims paid by the pure Medicare cases, although
this was not statistically significant (Table 3). Costs
in the month after the index month were lower than
those accrued during the index month, but monthly
costs increased during the following months.
Inpatient costs also accounted for the largest
proportion of costs during the index month, and
the month in which death occurred was particularly
costly. Outpatient and physician costs followed
inpatient costs during the index month.
Prescription drug costs were more than double for
the index month versus previous months and even
higher in the months thereafter (Table 3). Both
DME and private duty nursing/home health costs
increased across the study period.
Direct costs during insurance transition and before
and after Medicare eligibility
Commercial patients transitioned to Medicare an
average of 7.5 months after their initial ALS
diagnosis. For the period of nine months and
longer before the index month, the monthly cost
trend was 5% per month and in the period from
eight months to one month before the index
month, the monthly cost trend increased to 10%
per month. As discussed above, costs were highest
during the index month, with an average cost of
$9354 (Figure 4). From the index month forward
to the month of Medicare eligibility, the cost
averaged $4772/month, regardless of length of this
period (see light grey bars in Figure 4). Once
patients were Medicare eligible, costs increased,
averaging $7191/month, regardless of length of
this period. Of the $7191, $3559 was paid by
Medicare as COB (Figure 5). This is lower than
the cost after the index month by about $1000.
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Time and costs to disability milestones – pure
Medicare patients
As ALS progressed, the number of months to
milestones decreased and costs increased, indicating
general increased physical disability (Table 4). On
average, patients took 10.9 months to progress to
wheelchairs and accessories as measured by claims
submissions and then progressed through the
remaining milestones to hospice just 5.7 months
later. Interestingly, time to wheelchairs and acces-
sories was shorter than time to non-invasive (NIV)
ventilation. Total costs increased quickly as patients
became more severely physically impaired with the
largest and the second fastest cost jump occurring
from artificial nutrition/NIV to invasive ventilation/
speech device. Since KMSA total costs include the
cost for prior milestones in the costs of later ones,
the estimated cost for invasive ventilation/speech
device milestone included the cost for artificial
nutrition/NIV. Therefore, it took only an average
of 1.7 months from artificial nutrition/NIV to
invasive ventilation/speech device, but the estimated
total cost increased by $14,636 per patient.
Discussion
This research provided an overview of the burden of
ALS in the U.S. by defining an initial estimate of the
costs associated with common clinical disability
milestones in ALS medical care and estimating the
time to various disability milestones based on
insurance claim service dates. For both insurance
populations, costs increased in the nine months
before diagnosis. Costs were highest in the index
month, likely because of the claims filed for the visits
and tests associated with diagnosis. Inpatient facility
costs accounted for most costs during the index
month. Private duty nursing/home health costs
increased across the study period regardless of
insurance type, while outpatient costs generally
decreased after diagnosis, demonstrating a shift in
cost burden. DME costs were highest following the
index month for the pure Medicare population,
whereas these costs increased across the study
period for the commercial insurance population.
Patients appeared to progress to the disability
milestones more rapidly as their disease progressed
in severity, and their costs increased accordingly.
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Figure 1. Monthly costs to diagnosis for the pure Medicare population. Monthly costs were calculated as average monthly costs per
patient. Index month (black square); 1–8 months before (grey diamonds); 9 + months before (black triangles).
Table 2. Monthly costs per patient associated with ALS in the pure Medicare population*.
9 + months
pre-index
1–8 months
pre-index
Index
month
Post-index
months
Death
month
Inpatient facility $550 $1815 $7289 $1873 $2488
Outpatient facility $118 $322 $357 $245 $72
Physician $306 $488 $1483 $455 $384
Durable medical equipment $29 $62 $153 $506 $58
Private duty nursing/home health $111 $157 $943 $1417 $1418
Other $18 $41 $173 $55 $131
Total $1133 $2885 $10,398 $4551 $4551
*Calculated as the sum of the allowed costs divided by the sum of the member months.
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Figure 2. Total allowed costs after index date as a measure of survival time in a pure Medicare population.
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Figure 3. Monthly costs to diagnosis for the pure commercial population. Monthly costs were calculated as average monthly costs per
patient. Index month (black square); 1–8 months before (grey diamonds); 9 + months before (black triangles).
Table 3. Monthly costs per patient associated with ALS in the commercial population*.
9 + months
pre-index
1–8 months
pre-index Index month
Post-index
months
Death
month
Inpatient facility $430 $840 $4767 $1532 $2554
Outpatient facility $270 $859 $1940 $659 $732
Physician $288 $621 $1822 $589 $422
Durable medical equipment $33 $61 $151 $355 $1447
Private duty nursing/home health $11 $59 $135 $246 $1400
Prescription drugs $129 $194 $417 $603 $525
Other $7 $11 $122 $79 $90
Total $1167 $2645 $9354 $4063 $7190
*Calculated as the sum of the allowed costs divided by the sum of the member months.
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An analysis of a tertiary referral centre clinical
database consisting of 1471 ALS patients seen
between 1993 and 2007 estimated that the need
for gastrostomy (Stage 4A) and NIV (Stage 4B)
occurred at 77% and 80% through the disease
course, respectively, supporting the idea that the
increase in costs associated with corresponding
milestones in this study are directly correlated with
disease severity (23).
These U.S. results align with findings of previous
studies from other countries, suggesting that
increasing cost burden is independent of healthcare
system. For example, in Denmark, Jennum et al.
(14) also found costs were highest in the index
month, sharply rising during the months before
diagnosis. Other ex-U.S. studies have found ALS
costs increase with disease severity (4–8) and have
connected rising costs to characteristics of disease
progression such as wheelchairs and ventilators
(4,5,8). However, the actual costs associated with
ALS and when or how they are distributed across
disease progression vary, indicating that the cost of
ALS is multifactorial and likely to be dependent on
country-specific healthcare policies. In addition,
methodology differences such as how disease sever-
ity is defined (e.g. whether patients need caregiver
assistance (5) vs. involvement of different central
nervous system regions (7)) are also important when
considering data from different studies. For exam-
ple, a study using a similar approach and databases
(4), calculated different direct medical costs partly
because it did not divide costs according to before,
during and after diagnosis.
The strengths of this study include its nuanced
approach to disease progression, recognising that
costs are likely not equally distributed across the
three primary time-periods associated with diagno-
sis. This study determined that nine or more months
before diagnosis, average cost increased by 5%
monthly, which is annualised to 80%. Assuming
5.8% as the general annual cost trend (health
spending growth in the U.S. is projected to average
5.8% for 2015–2025 (24)), and 4% as the annual
cost increase attributed to aging for a population in
its 50s, the remaining 70.2% was caused by disease
progression. This analysis demonstrates that the
number of medical claims filed for ALS patients is
increasing even before diagnosis, which underscores
the need to identify patients earlier in their disease
course to help them potentially avoid expensive and
invasive tests and therapies.
This study also delineates the services underlying
these costs and compares pathways for two different
patient populations. Since the average age of ALS
onset is 58–60 years (25), understanding the cost-
associated patterns of ALS burden at these ages is
important. Finally, previous studies have not eval-
uated the time to, and costs associated with, specific
disability milestones. In this study, the average time
between artificial nutrition/NIV and between
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invasive ventilation/speech device was only 1.7
months, but the difference in costs was $14,636,
demonstrating that the relationship between time
and cost is not necessarily linear. Without a cure
(26), therapies are needed to delay the time to these
milestones, particularly those associated with an
acute increase in burden, and to increase survival.
Limitations of this study include an insufficient
number of disability milestones and deaths and
limited claim data due to the short follow-up period.
Consequently, the mean times to milestones might
have been underestimated and the ALS cost profiles
required special analysis techniques and assump-
tions to estimate variance.
Moreover, this analysis only includes Medicare
and commercial costs; out-of-pocket costs likely
increase economic burden significantly. A case study
of a young ALS patient in the U.S. estimated
household out-of-pocket expenses as 9% of the total
costs associated with the disease ($126,161 over the
10-year duration of the disease) (27). A Canadian
study of 50 patients with ALS estimated out-of-
pocket expenses to be even higher – 61% of direct
costs, amounting to an annual cost of $19,574 (12).
Importantly, this study found no association
between annual out-of-pocket cost and disease
duration, indicating that out-of-pocket costs con-
tinue to accumulate over the course of the disease.
In addition, the increasingly important roles of risk
adjustment (compensating insurers who enrol a
greater number of individuals with chronic dis-
eases), re-insurance (redistributing funds from com-
mercial plans to the new individual market to cover
unexpected demand) and risk pooling (creating
special programmes to provide a safety net for the
‘medically uninsurable’ population) were not
assessed in this analysis. Future studies may explore
whether delaying time to disability milestones
reduces costs, as agents that improve or preserve
function in ALS patients are developed.
Conclusions
This study found that for newly diagnosed ALS
patients in the U.S., medical costs are substantial.
Costs started to increase approximately nine months
before diagnosis for both Medicare and commercial
cases with the highest costs observed during the
index month. Costs post-diagnosis were lower than
during the index month but remained higher than
pre-diagnosis costs. Medical costs increased rapidly
and substantially with each disability milestone as
disease progressed, but no trend in costs was
observed during the coverage transition to
Medicare.
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